2023
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study
Milgrom S, Kim J, Pei Q, Lee I, Hoppe B, Wu Y, Hodgson D, Kessel S, McCarten K, Roberts K, Lo A, Cole P, Kelly K, Cho S. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. British Journal Of Haematology 2023, 201: 1192-1199. PMID: 36922022, PMCID: PMC10247420, DOI: 10.1111/bjh.18734.Peer-Reviewed Original ResearchConceptsRapid early respondersEvent-free survivalTotal lesion glycolysisBaseline total lesion glycolysisIntensive therapyRisk stratificationTumor burdenHodgkin's lymphomaEarly respondersMTV/TLGFour-year event-free survivalBaseline metabolic tumor burdenExcellent event-free survivalHigh-risk Hodgkin lymphomaChildren's Oncology Group studyPoor event-free survivalMaximum standardized uptake valueResponse-adapted approachBaseline PET scanMetabolic tumor burdenStandardized uptake valueIntensified therapyLesion glycolysisBaseline PETTumor SUV
2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 890-900. PMID: 34767937, PMCID: PMC9038118, DOI: 10.1016/j.ijrobp.2021.10.152.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapySlow early responseClassical Hodgkin lymphomaBulky diseaseOncology GroupHodgkin's lymphomaRetrospective analysisChildren's Oncology Group protocolsHigh-risk Hodgkin lymphomaRadiation treatment volumesCycles of doxorubicinHigh-risk patientsPhase 3 studyTime of progressionChildren's Oncology GroupPatterns of failureInitial siteABVE-PCConsolidation RTEligible patientsField relapseInitial relapseMedian followRelapse siteStage IIIB
2020
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley M, Rauf M, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel N, Hoppe B, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020, 135: 2365-2374. PMID: 32211877, DOI: 10.1182/blood.2019003877.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingNeoplasms, Radiation-InducedNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsRecurrenceRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalOverall survivalImmunoarchitectural patternsAssociated with worse progression-free survivalFive-year PFSLymphocyte-predominant Hodgkin lymphomaProgression-free survival ratesStudy of adult patientsSingle-agent rituximabLarge-cell transformationStage I diseaseMedian follow-upMulticenter retrospective studyMulti-institutional studyHodgkin lymphomaI diseaseRT cohortHistological variantsMedian agePrimary managementRetrospective studyRituximabAdult patientsRadiotherapy
2016
The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas
Stahl JM, Corso CD, Park HS, An Y, Rutter CE, Han D, Roberts KB. The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas. European Journal Of Surgical Oncology 2016, 43: 168-174. PMID: 27335080, DOI: 10.1016/j.ejso.2016.05.031.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasOverall survivalR1 resectionR0 resectionMargin statusNational Cancer Data BaseRetroperitoneal soft tissue sarcomaCox proportional hazards regressionPropensity scoreMultivariable logistic regression modelMedian overall survivalMicroscopic margin statusPre-operative RTReceipt of RTUnderwent R0 resectionSuperior overall survivalSmaller tumor sizeLow tumor gradeProportional hazards regressionLog-rank testRetroperitoneal soft tissueLogistic regression modelsLiposarcoma histologyR1 patientsRadiotherapy receiptPreoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ
Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber A, Gross CP. Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ. Breast Cancer Research And Treatment 2016, 158: 139-148. PMID: 27287780, PMCID: PMC5554869, DOI: 10.1007/s10549-016-3858-0.Peer-Reviewed Original ResearchConceptsContralateral breast cancerMagnetic resonance imagingPreoperative magnetic resonance imagingDuctal carcinomaMRI usePreoperative breast magnetic resonance imagingEnd Results-Medicare datasetInvasive contralateral breast cancerOccult contralateral breast cancerResonance imagingSynchronous contralateral breast cancerImpact of MRIStage-specific incidence ratesPreoperative MRI useBreast magnetic resonance imagingBreast cancer occurrenceCBC eventsCBC ratesCumulative incidencePropensity score approachIncidence rateInvasive diseaseBreast cancerCancer occurrenceOlder women
2015
The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer
Xu X, Herrin J, Soulos PR, Saraf A, Roberts KB, Killelea BK, Wang SY, Long JB, Wang R, Ma X, Gross CP. The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer. Health Services Research 2015, 51: 167-186. PMID: 26119176, PMCID: PMC4722219, DOI: 10.1111/1475-6773.12328.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBreast NeoplasmsComorbidityFemaleHealth ExpendituresHumansMedicareRetrospective StudiesSEER ProgramSocioeconomic FactorsUnited StatesConceptsBreast cancer careHospital referral regionsCancer careMedicare expendituresBreast cancerRadiation therapyTreatment factorsMean Medicare expendituresEnd Results-MedicareSpecific treatment modalitiesContribution of patientCost of careHighest spending quintilePatient factorsTreatment patternsTumor characteristicsCancer characteristicsTreatment modalitiesReferral regionsMedicare beneficiariesQuintilePatientsCancerCareTherapyHematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma
Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. Journal Of The American Academy Of Dermatology 2015, 72: 1010-1015.e5. PMID: 25981001, DOI: 10.1016/j.jaad.2015.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllograftsAutograftsBiopsy, NeedleFemaleFollow-Up StudiesGraft RejectionGraft SurvivalHematopoietic Stem Cell TransplantationHumansImmunohistochemistryLymphoma, T-CellLymphoma, T-Cell, CutaneousMaleMiddle AgedPanniculitisPositron-Emission TomographyRetrospective StudiesRisk AssessmentSampling StudiesSkin NeoplasmsTreatment OutcomeConceptsHematopoietic stem cell transplantationT-cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaAllogeneic hematopoietic stem cell transplantationPanniculitis-like T-cell lymphomaCutaneous T-cell lymphomaStem cell transplantationPCGD-TCLCell transplantationPrimary cutaneous γδ T-cell lymphomaCutaneous γδ T-cell lymphomaAutologous hematopoietic stem cell transplantationOutcome of HSCTAdvanced-stage mycosis fungoidesΓδ T-cell lymphomaPanniculitic T-cell lymphomaAggressive T-cell lymphomaMatched-related donorsMatched-unrelated donorsT-cell infiltratesPromising treatment modalityAggressive therapyMost patientsMycosis fungoidesInferior outcomes
2013
For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery
Sen S, Soulos PR, Herrin J, Roberts KB, Yu JB, Lesnikoski BA, Ross JS, Krumholz HM, Gross CP. For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. Surgery 2013, 155: 776-788. PMID: 24787104, PMCID: PMC4008843, DOI: 10.1016/j.surg.2013.12.009.Peer-Reviewed Original ResearchConceptsHospital ownership statusBreast-conserving operationsBreast-conserving surgeryUse of brachytherapyRadiation therapyOperative careBreast cancerMedicare beneficiariesOverall useReceipt of brachytherapyAdjuvant radiation therapyInvasive breast cancerFemale Medicare beneficiariesGreater overall useYears of ageShort life expectancyRetrospective studyRT modalityProfit hospitalsExpensive modalityOlder womenBrachytherapy useBreast brachytherapyHospitalBrachytherapyVariation in Receipt of Radiation Therapy After Breast-conserving Surgery
Feinstein AJ, Soulos PR, Long JB, Herrin J, Roberts KB, Yu JB, Gross CP. Variation in Receipt of Radiation Therapy After Breast-conserving Surgery. Medical Care 2013, 51: 330-338. PMID: 23151590, PMCID: PMC3596448, DOI: 10.1097/mlr.0b013e31827631b0.Peer-Reviewed Original ResearchConceptsUse of RTShort life expectancyRadiation therapyBreast cancerLife expectancyPrimary surgeonStage I breast cancerEarly-stage breast cancerRadiation oncologist densityAdjuvant radiation therapyI breast cancerReceipt of radiationBreast-conserving surgeryImpact of physiciansHierarchical logistic regression modelsLogistic regression modelsLonger life expectancyLE patientsRetrospective cohortLE groupOlder womenPatientsTreatment ratesWomenCancer
2012
Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity
Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP. Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. Journal Of The National Cancer Institute 2012, 105: 25-32. PMID: 23243199, PMCID: PMC3536640, DOI: 10.1093/jnci/djs463.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyProstate cancerMedicare beneficiariesGenitourinary toxicityEarly toxicityProton radiotherapyMultivariable logistic regressionPatterns of careMain outcome measuresType of radiotherapyMedicare reimbursementClinical benefitRetrospective studyPRT patientsOutcome measuresComprehensive cohortPRT useIMRT patientsPatientsSociodemographic characteristicsRadiotherapyCancerLogistic regressionMonthsSignificant differencesPatterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009
Presley CJ, Soulos PR, Herrin J, Roberts KB, Yu JB, Killelea B, Lesnikoski BA, Long JB, Gross CP. Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009. Journal Of Clinical Oncology 2012, 30: 4302-4307. PMID: 23091103, PMCID: PMC3675700, DOI: 10.1200/jco.2012.43.5297.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrachytherapyBreast NeoplasmsCombined Modality TherapyFemaleHumansMastectomy, SegmentalMedicareRetrospective StudiesUnited StatesConceptsWhole breast irradiationHospital referral regionsBone complicationsClinical characteristicsSkin complicationsEarly-stage breast cancerNational treatment patternsPercent of patientsShort-term complicationsBreast-conserving surgeryNational Medicare populationComplication rateTreatment patternsAge 66Breast cancerReferral regionsMedicare populationPatterns of useComplicationsMedicare beneficiariesTreatment groupsClinical practiceBreast brachytherapyBrachytherapyInstrumental variable analysis
2011
Geographic Analysis of the Radiation Oncology Workforce
Aneja S, Smith BD, Gross CP, Wilson LD, Haffty BG, Roberts K, Yu JB. Geographic Analysis of the Radiation Oncology Workforce. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: 1723-1729. PMID: 21493013, DOI: 10.1016/j.ijrobp.2011.01.070.Peer-Reviewed Original ResearchConceptsHealth service areasPrimary care physiciansCare physiciansRadiation oncologistsTotal physiciansOncology workforceRegression analysisArea Resource FilePrimary careRadiation oncology workforceHigh RORPhysiciansGeographic maldistributionResource FileOverall physician workforceOncologistsMinority populationsPhysician workforceRORHigh minority populationsHigher incomeGeographic variabilityPopulationYearsCare
2004
Relation of clinical success in coronary brachytherapy to dose
Singh HS, Yue N, Azimi N, Nath R, Roberts KB, Pfau S. Relation of clinical success in coronary brachytherapy to dose. The American Journal Of Cardiology 2004, 94: 847-852. PMID: 15464663, DOI: 10.1016/j.amjcard.2004.06.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCase-Control StudiesConnecticutCoronary AngiographyCoronary RestenosisCoronary VesselsDose-Response Relationship, RadiationFemaleFollow-Up StudiesHumansMaleMiddle AgedMultivariate AnalysisRadiotherapy DosageRetrospective StudiesStatistics as TopicTreatment OutcomeUltrasonography, InterventionalConceptsTreatment failureExternal elastic membraneTreatment successStent restenosisIntravascular ultrasoundAdequate dose deliveryRecurrent restenosisLesion patternsPrimary treatmentCoronary brachytherapyClinical successPatientsDose prescriptionRadiation delivery systemsArteryRestenosisGyDoseBrachytherapyDose thresholdRadiation delivery devicePotential causesDose deliveryIntravascular brachytherapyTreatment
2003
Brachytherapy for in-stent restenosis in general interventional practice A single institution's experience using four radiation devices
Singh HS, Roberts KB, Yue N, Nath R, Song GH, Azimi N, Pfau S. Brachytherapy for in-stent restenosis in general interventional practice A single institution's experience using four radiation devices. Cardiovascular Revascularization Medicine 2003, 4: 126-132. PMID: 14984712, DOI: 10.1016/s1522-1865(03)00183-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryBlood Vessel Prosthesis ImplantationBrachytherapyConnecticutCoronary AngiographyCoronary Artery BypassCoronary RestenosisCoronary StenosisEquipment DesignFamily PracticeFemaleFollow-Up StudiesHospital MortalityHumansMaleMiddle AgedRadiation DosageReoperationRetrospective StudiesStentsTreatment OutcomeConceptsMajor adverse cardiac eventsStent restenosisAverage treatment ageEffectiveness of brachytherapyAdverse cardiac eventsSingle institution experienceMinimal lumen diameterRandomized clinical trialsLesion-specific characteristicsSpectrum of patientsMACE rateHospital deathCardiac eventsRenal failureUnstable anginaClinical outcomesCoronary lesionsTreatment failureInstitution experienceFrequent presentationInterventional therapyClinical trialsGeneral populationInterventional practicePatients
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalities
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds
1998
Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy
Turner B, Knisely J, Kacinski B, Haffty B, Gumbs A, Roberts K, Frank A, Peschel R, Rutherford T, Edraki B, Kohorn E, Chambers S, Schwartz P, Wilson L. Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 77-84. PMID: 9422561, DOI: 10.1016/s0360-3016(97)00581-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyChemotherapy, AdjuvantCystadenocarcinoma, PapillaryDisease-Free SurvivalFemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesSalvage TherapyUterine NeoplasmsConceptsUterine papillary serous carcinomaWhole pelvic radiation therapyWhole-abdomen radiation therapyComplete surgical stagingDisease-free survivalActuarial disease-free survivalFIGO stage IPapillary serous carcinomaSurgical stagingActuarial OSOverall survivalSalvage rateStage IRadiation therapyUPSC patientsVaginal brachytherapyMyometrial invasionSerous carcinomaLDR brachytherapyRadiation Therapy Oncology Group (RTOG) grade 1DFS of patientsPara-aortic lymph node samplingConventional external beam radiotherapyFIGO stage IARTOG grade 3
1997
Treatment of recurrent pelvic and selected primary gynecologic malignancies with 241Am
Chung J, Roberts K, Peschel R, Nath R, Pourang R, Kacinski B, Wilson L. Treatment of recurrent pelvic and selected primary gynecologic malignancies with 241Am. International Journal Of Cancer 1997, 5: 227-234. PMID: 9372545, DOI: 10.1002/(sici)1520-6823(1997)5:5<227::aid-roi3>3.0.co;2-#.Peer-Reviewed Original ResearchConceptsRecurrent pelvic malignanciesPrimary gynecologic malignanciesPrimary radiotherapySurgical salvageMicroscopic diseasePelvic malignanciesPostoperative radiotherapyGynecologic malignanciesUltimate local control rateExternal beam radiation therapyGross primary tumorMedian patient ageLocal control rateTreatment of recurrentBeam radiation therapyMicroscopic residuumTreatment intentPatient ageSurgical resectionCurative therapyGynecologic tumorsGynecologic cancerControl ratePrimary tumorRadiation therapy
1996
Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium
Fishman D, Roberts K, Chambers J, Kohorn E, Schwartz P, Chambers S. Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium. Gynecologic Oncology 1996, 61: 189-196. PMID: 8626131, DOI: 10.1006/gyno.1996.0123.Peer-Reviewed Original ResearchConceptsClinical stage IOperable patientsInoperable patientsIntercurrent diseaseStage IRadiation therapyMedian survivalEndometrioid carcinomaMore deathsMedian disease-free intervalExclusive radiation therapyMedically Inoperable PatientsStage I groupCancer-specific survivalDisease-free intervalStage II diseaseOverall survival rateShorter overall survivalOperable diseaseOperable groupEndometrial cancerOverall survivalSuch patientsShorter survivalClinical stage